A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Voclosporin (Primary) ; Corticosteroid; Methylprednisolone; Prednisone
- Indications Lupus nephritis
- Focus Registrational; Therapeutic Use
- Acronyms AURA; AURA-LV
- Sponsors Aurinia Pharmaceuticals
- 05 Jun 2024 According to Aurinia Pharmaceuticals Inc. media release, data from the study will be presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15.
- 05 Jun 2024 Results presented in the Aurinia Pharmaceuticals Media Release.
- 14 May 2024 According to Aurinia Pharmaceuticals Inc. media release, data from the study were presented at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18.